Understand the source comparison
Best Peptides for Kidney Health: Evidence Comparison
BPC-157 VEGF pathway activation; angiogenesis in peritubular capillaries Ischemia-reperfusion injury models; cisplatin nephrotoxicity studies 200-500 mcg subcutaneously daily in rodent models (human equivalent dose unvalidated) Evidence limited to acute injury
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF pathway activation; angiogenesis in peritubular capillaries
- Ischemia-reperfusion injury models; cisplatin nephrotoxicity studies
- 200-500 mcg subcutaneously daily in rodent models (human equivalent dose unvalidated)
- Evidence limited to acute injury models; chronic CKD translation unclear; no Phase 3 trials
- Strongest preclinical evidence for acute renal injury; insufficient data for chronic progressive disease
- Thymosin Beta-4 (TB-500)
- NF-kB pathway modulation; inflammatory cytokine downregulation
- Diabetic nephropathy mouse models; wound healing human trials (indirect renal relevance)
- 5-10mg twice weekly subcutaneously in human wound healing studies
- Renal-specific human trials absent; Johns Hopkins cohort data confounded by multi-intervention design
- Plausible mechanism; established safety profile; requires dedicated renal trials
- Epithalon
- Mitochondrial membrane stabilisation; oxidative stress resistance in tubular cells
- Cell culture studies under high-glucose conditions; limited Russian clinical data
- 5-10mg subcutaneously for 10-day cycles in published protocols (poorly standardised)
- Western replication inconsistent; batch purity concerns; minimal validated human data
- Biologically plausible but evidence base too weak for confident recommendation
- Thymalin
- Thymic peptide fraction; immune system modulation
- Autoimmune nephritis models; immune senescence studies
- 10mg daily for 5-10 days per published Russian protocols
- Renal-specific evidence limited; mechanism less direct than BPC-157 or TB-500
- Potential adjunct in immune-mediated kidney disease; primary evidence base outside nephrology